Vaccines to Breast Cancer Based on p53 Mutants.
Abstract
P53 a tumor suppresser protein is commonly overexpressed and/or mutated in human breast cancer cells. We generated a number of different vaccine prototypes based on recombinant viruses, i.e., vaccinia or adenovirus or plasmid vectors expressing wild-type or mutant mouse p53 to test if they could induce immunity to tumors expressing wild-type or mutant p53. Experiments thus far have shown that vaccines expressing wild-type p53 induce partial protection against the growth of a tumor also expressing wild-type p53. The efficacy of the vaccine could be augmented by additional treatment with Interleukin 12 given after challenge with tumor cells.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1996
- Accession Number
- ADB218947
Entities
People
- Hildegund C. Ertl
Organizations
- University of Pennsylvania